Dospělá výška dětí, které se narodily malé na svůj gestační věk (SGA), s malou výškou v dětství (SGA-SS). Výsledky léčby růstovým hormonem z dat české národní databáze REPAR

Title in English	Adult height in children born small for gestational age (SGA) with persistent short stature (SGA-SS). Growth hormone treatment outcomes from data of the Czech countrywide REPAR database
Authors	TONI Ledjona KODYTKOVÁ Aneta PLACHÝ Lukáš JÍROVÁ Barbora ALDHOON HAINEROVÁ Irena ALEKSIJEVIĆ Darina ČERNÁ Jana DVOŘÁKOVÁ Marcela EL-LABABIDI Eva KALVACHOVÁ Božena KOCOURKOVÁ Kamila KOTVALOVÁ Ivana MAGNOVÁ Olga NOVOTNÁ Dana OBERMANNOVÁ Barbora POMAHAČOVÁ Renata PRŮHOVÁ Štěpánka SOUČEK Ondřej STRNADEL Jiří ŠICHOVÁ Lucie ŠKVOR Jaroslav ŠNAJDEROVÁ Marta ŠUMNÍK Zdeněk ZAPLETALOVÁ Jiřina ŠILAR Jiří KOLOUŠKOVÁ Stanislava LEBL Jan
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Česko-slovenská pediatrie
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.prolekare.cz/casopisy/cesko-slovenska-pediatrie/2023-s3/dospela-vyska-deti-ktere-se-narodily-male-na-svuj-gestacni-vek-sga-s-malou-vyskou-v-detstvi-sga-ss-vysledky-lecby-rustovym-hormonem-z-dat-ceske-narodni-databaze-repar-136398
Doi	http://dx.doi.org/10.55095/CSPediatrie2023/059
Keywords	small-for-gestational-age; SGA-SS; growth hormone; adult height; adjusted final height
Description	Of children born small for gestational age (SGA) with birth weight and/or birth length below -2 SD, about 10% fail to catch-up after birth. These children remain short over childhood (with height standard deviation score [ht-SDS] below -2.5 SDS) and end up as short adults. They are assigned as SGA-SS (small for gestational age with short stature). European Medicine Agency approved growth hormone therapy in SGA-SS already in 2003. Out of 1502 SGA-SS children that are registered in the Czech national database of growth hormone recipients REPAR, 397 children (221 boys) already completed growth and achieved near-final height. Growth hormone therapy (median dose 0.034 mg/kg/day) was initiated at age 8.5 years in boys (median; P5-95: 3.2-15.0) and 7.3 years in girls (3.9-13.5). The mean ht-SDS at treatment initiation was -3.21 (SD: 0.91). Treatment was terminated at age 16.2 years in boys (median; P5-95: 14.0-18.7) and 14.3 years in girls (12.4-17.3). By treatment termination, the patients have had gained 1.59 ht-SDS (mean) and have achieved near-final height -1.62 ht-SDS (SD: 0.97; p<0.0001 if compared to pre-treatment). Thus, majority of patients exceeded -2 SDS at treatment completion and achieved height within normal limits. After adjusting for ht-SDS at age 18 years, their height corresponded to ht-SDS -2.30 (SD: 1.09; p < 0.0001 if compared to pre-treatment). Growth hormone therapy was successful even after this adjustment that mildly underestimates the treatment effect, and led to mean height increase of 0.91 ht-SDS. Analysis results of the REPAR database confirm efficacy of growth hormone therapy in SGA-SS children and its potential to significantly improve the adult height.